E!1530 NK-ENGAGE
| Reference number | |
| Coordinator | Oncopeptides AB |
| Funding from Vinnova | SEK 5 000 000 |
| Project duration | October 2022 - September 2025 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The goal of developing engagers and evaluating them in relevant models was achieved. A relevant in vivo model for multiple myeloma was developed. The project enabled us to document beneficial effects of combining these engagers with an NK cell product. The potential for clinical use of engagers in autoimmune disease could be highlighted.
Expected long term effects
The project has laid the foundation for evaluating a new class of substances, and we expect that, in the long term, this could lead to new and improved therapies for cancer and autoimmune diseases.
Approach and implementation
Overall, the project plan worked well. Some mechanistic studies took longer than expected and extended longer. The part of the project involving the development of a relevant myeloma model was more complex than anticipated and required a greater degree of collaboration. This was managed with scheduled monthly meetings serving as a basis for decision-making and coordination. All parties were highly motivated and shared their expertise. It was a great asset that the parties were so complementary.